Cipla is an Indian multinational pharmaceutical major involved in the production of medicines with the potential to treat diabetes, cardiovascular disease, depression, weight control, and arthritis. The company recently made an announcement stating that over 200 drugs are in the development phase which when launched into the market would fetch revenues worth billions. It was founded in the year 1935 with headquarters in Mumbai. Whilst its inception it was known as The Chemical, Industrial & Pharmaceutical Laboratories. In the year 1984, the company was newly christened as Cipla Limited. The company has a robust Research and Development facility amongst all Pharma companies in the country.
Cipla produces 1500 products that covers broad range of categories. The Pharma major has a footprint in 150 countries. The estimated turnover is around USD 1.78 Billion. The mission statement of Cipla reiterates its commitment to ensure the access of quality and affordable medicines to all classes of patients. The company relies on technology and innovation to develop new health products, which indeed will support the day-to-day health needs of patients.
Categorized as a second largest pharmaceutical company in India, it is in the process of acquiring two US based Pharma companies. This acquisition will enhance the product base of Cipla. Upon successful acquisition the company will get access to 40 approved Abbreviated New Drug Applications (ANDAs), 30 Pharma products that are yet to be launched and 32 products that are currently being marketed. The major turning point of the company’s growth story was in the year 2001, when it launched antiretrovirals for treating HIV at a very low cost. All the more, Cipla also sells certain active pharmaceutical ingredients to other Pharma and personal care products companies. The company has around 34 manufacturing units spread across 8 locations in India.